Compare Deutsche Bank AG (DB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs State Street SPDR S&P Biotech ETF — how do they compare? Deutsche Bank AG trades at $38.21 (market cap $71.96B), while State Street SPDR S&P Biotech ETF trades at $158.23. The key difference: Deutsche Bank AG pays a 3.04% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| DB | XBI | |
|---|---|---|
Market Cap | $71.96B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $40.33 | $164.28 |
52-Week Low | $28.37 | $86.92 |
Dividend Yield | 3.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
